Cargando…
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is crit...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983822/ https://www.ncbi.nlm.nih.gov/pubmed/35401504 http://dx.doi.org/10.3389/fimmu.2022.845882 |
_version_ | 1784682040920113152 |
---|---|
author | Gonzalez-Perez, Maria Montes-Casado, Maria Conde, Patricia Cervera, Isabel Baranda, Jana Berges-Buxeda, Marcos J. Perez-Olmeda, Mayte Sanchez-Tarjuelo, Rodrigo Utrero-Rico, Alberto Lozano-Ojalvo, Daniel Torre, Denis Schwarz, Megan Guccione, Ernesto Camara, Carmen Llópez-Carratalá, M Rosario Gonzalez-Parra, Emilio Portoles, Pilar Ortiz, Alberto Portoles, Jose Ochando, Jordi |
author_facet | Gonzalez-Perez, Maria Montes-Casado, Maria Conde, Patricia Cervera, Isabel Baranda, Jana Berges-Buxeda, Marcos J. Perez-Olmeda, Mayte Sanchez-Tarjuelo, Rodrigo Utrero-Rico, Alberto Lozano-Ojalvo, Daniel Torre, Denis Schwarz, Megan Guccione, Ernesto Camara, Carmen Llópez-Carratalá, M Rosario Gonzalez-Parra, Emilio Portoles, Pilar Ortiz, Alberto Portoles, Jose Ochando, Jordi |
author_sort | Gonzalez-Perez, Maria |
collection | PubMed |
description | Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population. |
format | Online Article Text |
id | pubmed-8983822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89838222022-04-07 Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination Gonzalez-Perez, Maria Montes-Casado, Maria Conde, Patricia Cervera, Isabel Baranda, Jana Berges-Buxeda, Marcos J. Perez-Olmeda, Mayte Sanchez-Tarjuelo, Rodrigo Utrero-Rico, Alberto Lozano-Ojalvo, Daniel Torre, Denis Schwarz, Megan Guccione, Ernesto Camara, Carmen Llópez-Carratalá, M Rosario Gonzalez-Parra, Emilio Portoles, Pilar Ortiz, Alberto Portoles, Jose Ochando, Jordi Front Immunol Immunology Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8983822/ /pubmed/35401504 http://dx.doi.org/10.3389/fimmu.2022.845882 Text en Copyright © 2022 Gonzalez-Perez, Montes-Casado, Conde, Cervera, Baranda, Berges-Buxeda, Perez-Olmeda, Sanchez-Tarjuelo, Utrero-Rico, Lozano-Ojalvo, Torre, Schwarz, Guccione, Camara, Llópez-Carratalá, Gonzalez-Parra, Portoles, Ortiz, Portoles and Ochando https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Gonzalez-Perez, Maria Montes-Casado, Maria Conde, Patricia Cervera, Isabel Baranda, Jana Berges-Buxeda, Marcos J. Perez-Olmeda, Mayte Sanchez-Tarjuelo, Rodrigo Utrero-Rico, Alberto Lozano-Ojalvo, Daniel Torre, Denis Schwarz, Megan Guccione, Ernesto Camara, Carmen Llópez-Carratalá, M Rosario Gonzalez-Parra, Emilio Portoles, Pilar Ortiz, Alberto Portoles, Jose Ochando, Jordi Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title | Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title_full | Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title_fullStr | Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title_full_unstemmed | Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title_short | Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination |
title_sort | development of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mrna sars-cov-2 vaccination |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983822/ https://www.ncbi.nlm.nih.gov/pubmed/35401504 http://dx.doi.org/10.3389/fimmu.2022.845882 |
work_keys_str_mv | AT gonzalezperezmaria developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT montescasadomaria developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT condepatricia developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT cerveraisabel developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT barandajana developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT bergesbuxedamarcosj developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT perezolmedamayte developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT sancheztarjuelorodrigo developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT utreroricoalberto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT lozanoojalvodaniel developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT torredenis developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT schwarzmegan developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT guccioneernesto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT camaracarmen developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT llopezcarratalamrosario developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT gonzalezparraemilio developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT portolespilar developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT ortizalberto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT portolesjose developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination AT ochandojordi developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination |